Home2022

2022 July

Credibly reintermediate backend ideas for cross-platform models. Continually reintermediate integrated processes through technically sound intellectual capital.
Medigen applies for Australian vaccine approval

Excerpt Medigen Vaccine Biologics Corp (高端疫苗) has applied to the Australian medicines regulator for provisional approval of its COVID-19 vaccine. Article Summary Medigen Vaccine Biologics Corp applied to Australian medicines regulator for provisional approval of the COVID-19 vaccine and has delivered the necessary documents to the Australian Therapeutic Goods Administration (TGA), but did not say...

Prestige Biopharma announces International Non-proprietary Name for PBP1510

Excerpt Prestige Biopharma Limited, announced that its first-in-class antibody PBP1510 has acquired an International Nonproprietary Name (INN) of ‘Ulenistamab’ and was placed on the INN Recommended List by the World Health Organization (WHO). Article Summary Prestige Biopharma Limited first-in-class antibody has acquired an International Nonproprietary Name (INN) of ‘Ulenistamab’. INN-Ulenistamab, which is also known as...

Astellas Announces the Opening of Its New Gene Therapy Manufacturing Facility in North Carolina

Astellas Pharma Inc has announced the opening of a new late stage clinical and commercial manufacturing facility in Sanford, North Carolina, US. The facility will allow the company to expand its resources and team to establish a robust, global supply chain and expand its therapeutic and geographic scope. Article Summary The new 135,000 square-foot state-of-the-art...

Center for Breakthrough Medicines Accelerates Plans to Build the Largest Cell Therapy Manufacturing Operation in the World

The Center for Breakthrough Medicines (CBM) in partnership with the Discovery Labs has accelerated the plans to build capacity to manufacture more than 10,000 patient therapies in direct response to the critical shortage of cell therapy supply, which will help patients win their courageous battles against cancer. Article Summary Planning has begun on a massive...

Prescient Therapeutics Unveils its New Cell Therapy Platform – CellPryme-M

A clinical-stage oncology company Prescient Therapeutics (PTX) has launched its second cell therapy platform, CellPryme-M, which produces superior cells with greater cancer killing activity. This platform opens commercial opportunities for the company to incorporate it into third-party manufacturing processes. Article Summary PTX has developed this new platform technology in association with its research partner, Peter...

The European Investment Bank (EIB) has provided €75 million to the Institut Pasteur de Dakar for the construction of a new vaccine manufacturing facility.

Excerpt Large-scale funding for the Institut Pasteur de Dakar’s new vaccine manufacturing facility, a leader in the area in Africa. The facility, which would produce up to 300 million doses per year against COVID-19 and other endemic diseases, is projected to considerably reduce Africa’s reliance on imported vaccines and support equal access to medicines. This...

World Bank Support for Country Access to COVID-19 Vaccines

Excerpt The World Bank has approved $9.5 billion in operations to assist vaccination rollout in 77 countries as of June 15, 2022. Article Summary The World Bank Group is collaborating with partners on the world’s largest vaccine programme to combat the COVID-19 pandemic. The World Bank’s Board of Executive Directors adopted a $6 billion Global...